Taken together, our results identify a new mechanism showing that the ERK1/2-Bcl-2/Bax signaling pathway is responsible for Gem resistance and suggest that targeting the ERK1/2-Bcl-2/Bax signaling pathway may overcome gemcitabine resistance in human pancreatic cancer. The gene discussed is BAX; the disease is familial pancreatic carcinoma.